

This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). This means that any user shall be free to copy and redistribute the material in any medium or format, also for commercial purposes, provided proper credit is given to the Authors as well as the original publisher.

Erratum

In the article 'Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.' [Cell Physiol Biochem 2018; 47(3):957-971. doi: 10.1159/000490140] by Yu et al., there is an image assembly error in Figure 1A panel a, in which the images for both "A498" and "Caki" groups were erroneously duplicated with the images from the "Niclosamide" groups of Fig. 6A and Fig. 6B, respectively. This error was caused by a misunderstanding by an author who believed the "niclosamide" alone treatment groups should be used as common reference/control for the combination treatment groups and should be the same as that presented in Figure 6AB since the experiments were done at the same time. Here, we corrected the error with the correct niclosamide dose-dependent treatment results from independent batches of experiments. The authors state that this errors do not adversely impact the conclusion of the original work. The authors apologize for any inconvenience caused by the errors to the journal and scientific community. Additionally, a production error occurred for which Figure 3 was uploaded twice instead of Figure 4. The corrected Figure 1 and Figure 4 are shown below.



